Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Drugs Derived from New Compound Could Cure Three Tropical Diseases

By Ryan Bushey | August 8, 2016

Scientists are one step closer to developing a potent treatment for Chagas disease, leishmaniasis, and human trypanosomiasis. All three are tropical diseases that affect 20 million people worldwide and can cause an estimated 50,000 deaths a year.

One feature these diseases all have in common is that parasites with similar biologies and genomic sequences induce these infections, according to University of York. However, each pathogen causes different symptoms.

The researchers scanned a library owned by Novartis, which was filled with over three million chemical compounds. A phenotypic screen was performed against the live parasites using these elements in order to identify the most potent.

Please follow R&D Magazine on LinkedIn

The final compound, named GNF6702, had the greatest impact against a weak spot found in all three parasites, reported Reuters.

The compound was modified to test in mice. Results showed GNF6702 could successfully cure the disease in the animal subjects without causing harmful side effects.

No dangerous side effects in mice may mean this compound could present a safer alternative to existing tropical disease drugs.

The next phase of this project will include toxicity testing before moving onto human trials.

The study was published in the journal Nature.


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50